Portola Pharmaceuticals (PTLA) Given News Impact Rating of 0.10

News stories about Portola Pharmaceuticals (NASDAQ:PTLA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.8806753651199 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

Portola Pharmaceuticals (NASDAQ:PTLA) opened at $45.10 on Wednesday. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24. The stock has a market cap of $2,940.00, a PE ratio of -10.44 and a beta of 1.18. Portola Pharmaceuticals has a twelve month low of $28.43 and a twelve month high of $67.10.

A number of brokerages have commented on PTLA. Zacks Investment Research upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Citigroup restated a “buy” rating and set a $74.00 price objective on shares of Portola Pharmaceuticals in a research report on Thursday, December 28th. BidaskClub downgraded shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. Oppenheimer set a $80.00 price objective on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Finally, Goldman Sachs Group began coverage on shares of Portola Pharmaceuticals in a research report on Friday, December 1st. They set a “buy” rating and a $75.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $70.65.

In other news, Director Henry Ward Wolff sold 12,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2018/02/14/portola-pharmaceuticals-ptla-given-news-impact-rating-of-0-10.html.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Insider Buying and Selling by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply